Business profile & competitive position
The Clorox Company operates in the Consumer Defensive sector within the Household & Personal Products industry, selling branded consumer and professional cleaning, food, and household items. Its consumer portfolio includes Clorox, Pine-Sol, Glad, Fresh Step, Kingsford, Hidden Valley, Brita, and Burt’s Bees, while professional products are marketed under Purell, CloroxPro, and CloroxHealthcare. According to its most recent 10-K, Clorox generated fiscal 2026 net sales of $6.7 billion, employed about 9,200 people, operated in approximately 25 countries, and sold into roughly 95 markets. In April 2026, the company completed the acquisition of GOJO Industries, adding the Purell hand-hygiene franchise and expanding its business-to-business health and hygiene footprint.
The company’s reported margin and return metrics send somewhat conflicting signals. The net margin of 9.4% is positive but moderate for a consumer staples operator, suggesting pricing power and cost control that are competitive but not exceptional. The return on equity, however, is reported at -1,920.6%, which is less a verdict on operating profitability than a reflection of a deeply negative equity base. When net income is positive but common equity is negative, ROE flips to an extreme negative number and loses its usual interpretation as a “return on shareholder capital” measure. In other words, the margin figure is more useful than the headline ROE for judging current business health.
Distribution concentration is a key structural feature that defines the competitive position. Walmart alone accounted for 26% of consolidated FY2026 net sales, and the five largest customers together represented about half of net sales. That concentration creates negotiating leverage for retailers and means Clorox’s performance can be affected by零售商 order timing, promotional calendars, and shelf-space decisions in ways that a more diversified sales base might not. Beta is low at 0.58, consistent with a defensive staples business, but the supply-side customer concentration remains a real vulnerability.
Financial posture
As of the current snapshot, Clorox carries a market capitalization of $13.4 billion and trades at a trailing P/E of 19.9. The stock price is $110.77, well above its 50-day exponential moving average of $93.86, and the 14-day RSI is 83.5—a level typically associated with strong near-term momentum. Net margin remains 9.4%, while beta at 0.58 classifies the name as lower-volatility relative to the broader market.
The most unusual number is again the -1,920.6% ROE. Because Clorox is profitable on an operating level, this distortion almost certainly comes from liabilities exceeding accounting common equity—likely amplified by debt, share repurchases, and the GOJO acquisition balance-sheet impact. For valuation purposes, investors should treat the P/E and margin as more reliable signals than ROE until the equity base normalizes. The company does not appear cheap on an absolute P/E basis near 20x, but that level is in line with many large-cap consumer defensive names once adjusted for sector norms and the premium sometimes assigned to steady cash-flow businesses.
One additional consideration from the 10-K: fiscal 2026 saw declines in organic sales and earnings, with diluted EPS down 26%. Management attributed part of the pressure to macroeconomic headwinds and to ERP-transition timing that had pulled some sales into fiscal 2025. That context helps explain why earnings comparisons may look uneven year over year and why margin recovery and sales stabilization are central themes for analysts.
Strategic priorities & outlook
Clorox’s own SEC filing frames the near-term agenda around its IGNITE strategy, organized into four choices: fueling long-term profitable growth, innovating consumer experiences, reimagining how the company and its people work, and continuously evolving the product portfolio. Operationally, management says it is focused on three work streams.
First, it is completing and optimizing a new enterprise resource planning (ERP) system and broader digital transformation, which it expects to generate long-term efficiencies across supply chain, digital commerce, innovation, and brand building. The FY2026 commentary makes clear this transition still has timing impacts, so the ERP rollout is not only a cost-saving project but also a near-term source of revenue noise.
Second, Clorox intends to invest in strong brands, strategic digital capabilities, and a streamlined operating model to build what it calls a more resilient company and to deliver consistent, profitable growth. This implies continued marketing and innovation spending rather than deep cost-cutting.
Third, it is advancing health and hygiene expansion and portfolio optimization, which includes integrating GOJO and growing professional and institutional markets. The GOJO deal, completed in April 2026, is the most tangible near-term catalyst. It added Purell alongside the existing CloroxPro and CloroxHealthcare lines and increases the company’s exposure to higher-margin, recurring business-to-business demand.
A final operational note from the 10-K: the Glad bags and wraps venture with Procter & Gamble expired on January 31, 2026. Clorox purchased P&G’s 20% interest, and Glad retained core intellectual property licenses on a royalty-free basis. This removes a joint-venture partner from the brand and may change reported economics for the Glad segment, even if consumer shelf presence looks the same.
Macro & geopolitical exposure
As a household and personal-products company, Clorox sits squarely in the low-beta, defensive consumer staples world, but that does not make it immune to macroeconomic forces. The sector is exposed to commodity inputs such as resins, chemicals, oils, paper pulp, and packaging materials. Swings in oil prices affect both raw materials and freight costs, while pulp markets influence Kingsford and tissue-related items. Any sustained tariffs on imported resins, chemicals, or finished goods from key manufacturing regions could pressure cost of goods sold.
Regulation is another real exposure. Cleaning products are subject to the EPA, health and hygiene items can fall under FDA oversight, and labeling and marketing claims are policed by the FTC. The professional Purell and CloroxHealthcare lines add healthcare-adjacent regulatory complexity, including requirements around efficacy claims and facility distribution.
Because Clorox operates in about 95 markets, currency translation is a recurring factor for reported sales and earnings. A stronger U.S. dollar would reduce the value of overseas revenue when converted back. On the demand side, private-label competition tends to strengthen when consumers trade down, which can pressure branded pricing and volume. Trade policy, labor costs in manufacturing and distribution, and retailer consolidation are all plausible channels through which macro or geopolitical shifts could show up in Clorox’s results.
Recent developments
The most recent headlines illustrate how the market is currently framing the stock: as a defensive, high-yield play that has been under pressure.
- On November 13, 2026, 247wallst.com published “A Record-High Dividend Yield Can Be a Warning Sign. Just Ask Pfizer.” The article uses Clorox as a cautionary example in the record-high-yield discussion, suggesting that very elevated yields can sometimes reflect financial stress or a market pricing in dividend risk rather than a pure opportunity.
- On November 12, 2026, defenseworld.net reported that Commonwealth Equity Services LLC acquired Clorox shares. This is a routine institutional filing disclosure, but it does show that at least one advisory/brokerage entity was adding exposure around current levels.
- On November 11, 2026, schaeffersresearch.com noted that the Nasdaq rallied 464 points as a tech rally built. This headline is not CLX-specific, yet it matters for context: Clorox’s low beta means it often moves independently of high-beta tech surges, and the breadth of any rally can influence short-term relative performance.
- On November 9, 2026, fool.com ran “3 Magnificent High-Yield Dividend Stocks to Buy Near Their 52-Week Lows,” which included Clorox among the featured names. That positioning reinforces a narrative of a beaten-down consumer defensive stock offering an elevated yield.
Taken together, the news flow suggests investor attention is focused on income sustainability, valuation after a sharp rally, and whether the defensive earnings profile can hold up against broader market rotation. The stock price of $110.77 and RSI of 83.5 show that much of this sentiment may already be reflected in price action.
Earnings behavior & post-earnings drift
Clorox has a solid recent earnings track record. Over the last eight reported quarters, the company has beaten earnings estimates 6 out of 8 times, or 75%, with an average surprise of 11.1%. More interesting is how the stock has behaved after the release: the average 5-day price move following earnings across those quarters is +7.03%, and the post-earnings drift direction is classified as up.
The four most recent quarters highlight both the consistency and the volatility of that drift.
- November 2, 2026: EPS of $1.55 versus the estimate of $1.07, a 44.9% positive surprise. The stock rose 4.34% the next day and 17.39% over the following five trading sessions.
- August 3, 2026: EPS of $1.66 versus $1.64, a modest 1.2% beat. The stock gained 6.52% the next day and 9.61% over five days.
- April 30, 2026: EPS of $1.64 versus $1.55, a 5.8% beat. Despite beating, the stock fell -9.67% the next day and -4.49% over five sessions.
- February 3, 2026: EPS of $1.39 versus $1.43, a -2.8% miss. The stock still rose 2.43% the next day and 5.63% over five days.
Those results show that beats generally generate rallies and that the overall post-earnings drift has been positive, but the reaction is not always predictable in a single quarter. The upcoming report is scheduled for February 2, 2027, after the market close, with an unofficial consensus EPS estimate of $0.984. Given the November report sparked a double-digit percentage rally and the RSI is now 83.5, expectations heading into February may already be elevated, which can affect how a “beat” is received.
Frequently Asked Questions
Why is Clorox’s ROE reported as -1,920.6% when the company is profitable?
ROE equals net income divided by shareholders’ equity. Clorox has a positive net margin of 9.4%, but its accounting common equity is negative—likely due to debt, share buybacks, and acquisition-related balance sheet impacts. A negative denominator produces an extreme negative ROE, so the figure is mathematically correct but not a useful measure of operating profitability.
How concentrated is Clorox’s customer base?
Very concentrated. Walmart alone accounted for 26% of fiscal 2026 net sales, and the five largest customers together represented about half of consolidated net sales. That concentration gives large retailers significant negotiating leverage and means order timing can materially affect quarter-to-quarter results.
How has CLX historically performed in the days after earnings?
Over the last eight quarters, CLX has beaten earnings estimates 75% of the time with an average surprise of 11.1%. The average 5-day post-earnings move has been +7.03%, classified as an upward drift. The November 2026 report produced a 17.39% five-day rally, while the April 2026 beat saw a 9.67% one-day drop, showing that individual reactions can still diverge.
For a deeper synthesis of where Wall Street currently stands on Clorox—consensus rating changes, estimate revisions, and the latest risk factors—view the full institutional verdict on the platform.
| Reported | Actual | Estimate | Surprise | 1D Move | 5D Move |
|---|---|---|---|---|---|
| 2026-11-02 | $1.55 | $1.07 | +44.9% | +4.34% | +17.39% |
| 2026-08-03 | $1.66 | $1.64 | +1.2% | +6.52% | +9.61% |
| 2026-04-30 | $1.64 | $1.55 | +5.8% | -9.67% | -4.49% |
| 2026-02-03 | $1.39 | $1.43 | -2.8% | +2.43% | +5.63% |
| 2025-11-03 | $0.85 | $0.818 | +3.9% | - | - |
| 2025-07-31 | $2.87 | $2.2 | +30.5% | - | - |
Previous CLX editions
Get the institutional verdict on CLX
Seven-seat 21-ERT council. Pre-print forecast signed before the earnings release. Post-print grade, published in public. Every verdict sealed with a cryptographic receipt.
Read the CLX verdict at Gamma QCVerify authenticity
Every Gamma QC verdict is signed with a cryptographic receipt at issuance. Independently verify any published verdict at attest.gammaqc.com. This educational primer is content-only and not itself signed; the institutional verdict at the link above is.